Botox demand underpins Allergan results

New Jersey HQ’d Allergan posted underlying earnings of US$3.35 per share, around 4c better than consensus

picture of syringe
Botox sales are booming

Botox maker Allergan PLC beat forecasts despite losses in the latest quarter more than doubling on a year ago.

The Dublin-based company has been in the thick of the M&A activity in the pharma sector and was tipped last week by the Wall Street Journal to be lining up a bid for rival Biogen.

A US$160bn merger with Pfizer fell through in April after the Obama administration cracked down on tax inversion deals.

New Jersey HQ’d Allergan posted underlying earnings of US$3.35 per share, around 4c better than consensus, on sales of US$3.7bn

Underlying profit [adjusted EBITDA] from continuing operations was US$1.94bn (US$2.08bn), with the dip blamed on Alzheimer drug Namenda going off patent. 

Botox sales rose 14% to US$720mln, dry eye treatment Retasis jumped 20% US$391mln but Namenda eased 19% to US$167mln.

Statutory losses for the quarter were US$501.7mln against US$243mln a year ago.

For the whole of 2016, the pharma expects revenues of between US$14.65bn -14.9bn and underlying earnings per share of US$13.75c – US$14.20c.


Quick facts: Allergan

Price: 178.4 USD

Market: NYSE
Market Cap: $58.69 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

1 day, 5 hours ago

2 min read